Matthew Rizzo is the long-time head of OrbiMed's dedicated Royalty and Credit Opportunities team, where he has led over $6 billion of investments in structured credit and royalty deals rather than traditional equity investing. He brings 30 years of healthcare experience spanning big pharma, specialty biotech, and alternative asset management, including hands-on operating and transaction work in pharmaceutical licensing and acquisitions before moving into investing. Matthew Rizzo is the long-time head of OrbiMed's dedicated Royalty and Credit Opportunities team, where he has led over $6 billion of investments in structured credit and royalty deals rather than traditional equity investing. He brings 30 years of healthcare experience spanning big pharma, specialty biotech, and alternative asset management, including hands-on operating and transaction work in pharmaceutical licensing and acquisitions before moving into investing.